Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA: Canada Impact+ Research Training Awards - Doctoral

McGill University

$120,000.00

The Role of Adenosine Signaling in Tumor Immune Supression and Immunotherapy Resistance

EF 2025-26

Résumé
"Cancer immunotherapy has changed how we treat many tumors by helping the immune system recognize and attack cancer cells. However, these treatments do not work for everyone. Many patients either fail to respond or develop resistance, reminding us that cancer often finds ways to hide from or disable the immune system. Tumors often protect themselves by creating a chemical environment that weakens immune cells. Dr. Stagg’s lab studies one of these systems, which involves a molecule called adenosine. Adenosine is naturally present in every cell of the body and plays important roles in normal cellular function and energy balance. However, tumors can exploit this molecule to reduce the activity of immune cells that would otherwise attack them. Specific proteins control how much adenosine is produced and how it moves between cells, shaping the strength of the immune response within the tumor. Recent work from his group has shown that blocking a key regulator of this pathway can restore the ability of cancer-fighting immune cells to control tumor growth, pointing to new strategies to improve immunotherapy. During my doctoral research, I aim to investigate how these adenosine-related pathways function in specific immune cell populations and how they contribute to resistance to immune checkpoint inhibitors. By using mouse models, multi-omics analysis, and human tumor datasets, I aim to contribute to understanding how these pathways influence anti-tumor immunity and response to immunotherapy. By clarifying how tumors suppress immune activity through these mechanisms, this research will help guide the development of more precise and effective cancer therapies, with the goal of expanding the number of patients who benefit from immunotherapy."
Programme
DRA: Canada Impact+ Research Training Awards - Doctoral
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
568170
Name
Perez-Sanchez Paula
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Canada Impact+ Research Training Awards - Doctoral
Projecttitle
The Role of Adenosine Signaling in Tumor Immune Supression and Immunotherapy Resistance
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA: Canada Impact+ Research Training Awards - Doctoral
Keyworddelim
Cancer; Immunotherapy; Personalized Medicine; Treatment Efficacy; Tumor Microenvironment
Abstract
"Cancer immunotherapy has changed how we treat many tumors by helping the immune system recognize and attack cancer cells. However, these treatments do not work for everyone. Many patients either fail to respond or develop resistance, reminding us that cancer often finds ways to hide from or disable the immune system. Tumors often protect themselves by creating a chemical environment that weakens immune cells. Dr. Stagg’s lab studies one of these systems, which involves a molecule called adenosine. Adenosine is naturally present in every cell of the body and plays important roles in normal cellular function and energy balance. However, tumors can exploit this molecule to reduce the activity of immune cells that would otherwise attack them. Specific proteins control how much adenosine is produced and how it moves between cells, shaping the strength of the immune response within the tumor. Recent work from his group has shown that blocking a key regulator of this pathway can restore the ability of cancer-fighting immune cells to control tumor growth, pointing to new strategies to improve immunotherapy. During my doctoral research, I aim to investigate how these adenosine-related pathways function in specific immune cell populations and how they contribute to resistance to immune checkpoint inhibitors. By using mouse models, multi-omics analysis, and human tumor datasets, I aim to contribute to understanding how these pathways influence anti-tumor immunity and response to immunotherapy. By clarifying how tumors suppress immune activity through these mechanisms, this research will help guide the development of more precise and effective cancer therapies, with the goal of expanding the number of patients who benefit from immunotherapy."
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Perez-Sanchez, Paula
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~